STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
复制标题
DOI:
10.1038/s41416-018-0188-5
复制
发表时间:
2018-08
影响因子:
8.8
通讯作者:
Koti M
中科院分区:
文献类型:
--
作者:
Ghaffari A;Peterson N;Khalaj K;Vitkin N;Robinson A;Francis JA;Koti M
High-grade serous carcinoma (HGSC) of the ovary is predominantly diagnosed at late stages and primarily treated with debulking surgery followed by platinum/taxane-based chemotherapy. Although certain patients benefit significantly from currently used chemotherapy, there are patients who either do not respond or have an inadequate duration of response. We previously showed that tumours from chemoresistant patients have an immunosuppressed pre-existing tumour immune microenvironment with decreased expression of Type I Interferon (IFN1) genes. Efficacy of a ‘STimulator of INterferon Genes’ agonist was evaluated in combination with carboplatin chemotherapy and PD-1 immune checkpoint blockade therapy in the ID8-Trp53−/− immunocompetent murine model of HGSC. Treatment with STING agonist led to decreased ascites accumulation and decreased tumour burden. Survival of mice treated with a combination of carboplatin, STING agonist and anti-PD-1 antibody was the longest. Tumour immune transcriptomic profiling revealed higher IFN response, antigen presentation and MHC II genes in tumours from STING agonist-treated mice compared to vehicle controls. Flow cytometry analysis revealed significantly higher intra-tumoural PD-1+ and CD69+CD62L−, CD8+ T cells in STING agonist-treated mice. These findings will enable rational design of clinical trials aimed at combinatorial approaches to improve chemotherapy response and survival in HGSC patients.
登录
查看更多内容
影响因子:
--
作者:
Spranger S;Sivan A;Corrales L;Gajewski TF
通讯作者:
Gajewski TF
影响因子:
8.8
作者:
Corrales L;Glickman LH;McWhirter SM;Kanne DB;Sivick KE;Katibah GE;Woo SR;Lemmens E;Banda T;Leong JJ;Metchette K;Dubensky TW Jr;Gajewski TF
通讯作者:
Gajewski TF
DOI:
10.1038/nrc4019
发表时间:
2015-11
期刊:
Nature reviews. Cancer
影响因子:
--
作者:
Bowtell DD;Böhm S;Ahmed AA;Aspuria PJ;Bast RC Jr;Beral V;Berek JS;Birrer MJ;Blagden S;Bookman MA;Brenton JD;Chiappinelli KB;Martins FC;Coukos G;Drapkin R;Edmondson R;Fotopoulou C;Gabra H;Galon J;Gourley C;Heong V;Huntsman DG;Iwanicki M;Karlan BY;Kaye A;Lengyel E;Levine DA;Lu KH;McNeish IA;Menon U;Narod SA;Nelson BH;Nephew KP;Pharoah P;Powell DJ Jr;Ramos P;Romero IL;Scott CL;Sood AK;Stronach EA;Balkwill FR
通讯作者:
Balkwill FR
影响因子:
17.1
作者:
Fu J;Kanne DB;Leong M;Glickman LH;McWhirter SM;Lemmens E;Mechette K;Leong JJ;Lauer P;Liu W;Sivick KE;Zeng Q;Soares KC;Zheng L;Portnoy DA;Woodward JJ;Pardoll DM;Dubensky TW Jr;Kim Y
通讯作者:
Kim Y
影响因子:
32.4
作者:
Deng, Liufu;Liang, Hua;Xu, Meng;Yang, Xuanming;Burnette, Byron;Arina, Ainhoa;Li, Xiao-Dong;Mauceri, Helena;Beckett, Michael;Darga, Thomas;Huang, Xiaona;Gajewski, Thomas F.;Chen, Zhijian J.;Fu, Yang-Xin;Weichselbaum, Ralph R.
通讯作者:
Weichselbaum, Ralph R.